专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007069827A1 PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE LAYER AND FAST RELEASE LAYER FOR TREATMENT OF HYPERLIPIDEMIA AND ARTERIOSCLEROSIS 审中-公开
标题翻译：具有扩展释放层和快速释放层的药物组合物用于治疗高磷脂酰胆碱和血栓形成
公开(公告)号：WO2007069827A1
公开(公告)日：2007-06-21
申请号：PCT/KR2006/004738
申请日：2006-11-13
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee Jong , KI, Min Hyo , LEE, Jin Woo , KIM, Byoung Su
发明人： SHIN, Hee Jong , KI, Min Hyo , LEE, Jin Woo , KIM, Byoung Su
IPC分类号： A61K9/22 , A61P9/10
CPC分类号： A61K9/209
摘要： The present invention provides a pharmaceutical composition comprising a therapeutically amount of nicotinic acid and a nicotinic acid compound or mixtures thereof in a sustained release form and a therapeutically amount of a HMG-CoA reductase inhibitor in a fast release form which can optimally treat hyperlipidemia and arteriosclerosis by minimizing the interaction of two drugs. The pharmaceutical composition of the present invention comprising a coated two- layer tablet a) one sustained release layer containing nicotinic acid and a nicotinic acid compound or mixtures thereof, together with a sustained release polymer and b) another fast release layer containing a HMG-CoA reductase inhibitor, a film- or layer- forming agent, a re- crystallization inhibitor and a plasticizer, can minimize the interaction of the two drugs via controlled release profile and treat optimally hyperlipidemia and arteriosclerosis.
摘要翻译：本发明提供药物组合物，其包含治疗量的烟酸和烟酸化合物或其缓释形式的混合物和治疗量的快速释放形式的HMG-CoA还原酶抑制剂，其可以最佳地治疗高脂血症和动脉硬化通过最小化两种药物的相互作用。本发明的药物组合物包含包被的两层片剂a）一个含有烟酸和烟酸化合物或其混合物的持续释放层以及持续释放聚合物，以及b）包含HMG-CoA的另一快速释放层还原酶抑制剂，成膜剂或成层剂，再结晶抑制剂和增塑剂，可以通过控制释放曲线最小化两种药物的相互作用，并治疗最佳高脂血症和动脉硬化。

2. 发明申请

WO2006033505A8 PAROXETINE CHOLATE OR CHOLIC ACID DERIVATIVE SALTS, AND COMPOSITION COMPRISING PAROXETINE AND CHOLIC ACID OR CHOLIC ACID DERIVATIVES 审中-公开
标题翻译：异黄酮或胆酸衍生物，以及包含PAROXETINE和胆酸或胆酸衍生物的组合物
公开(公告)号：WO2006033505A8
公开(公告)日：2006-09-14
申请号：PCT/KR2004003477
申请日：2004-12-28
申请人： CHONG KUN DANG PHARM CORP , LEE SANG JOON , SHIN HEE JONG , KI MIN HYO , LEE SU KYOUNG , KIM BOK YOUNG , LEE HONG WOO
发明人： LEE SANG JOON , SHIN HEE JONG , KI MIN HYO , LEE SU KYOUNG , KIM BOK YOUNG , LEE HONG WOO
IPC分类号： C07D405/12 , A61K31/445 , A61P25/24
CPC分类号： C07D405/12 , C07J43/00
摘要： Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.
摘要翻译：本文公开了帕罗西汀胆酸盐或胆酸衍生物盐和包含帕罗西汀和胆酸或其衍生物的组合物。还公开了包含帕罗西汀盐或组合物的药物组合物。作为帕罗西汀的口腔崩解片剂，可以将药物组合物配制成无水的口服制剂。

3. 发明申请

WO2006080780A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BISPHOSPHONATE FOR IMPROVING ORAL ABSORPTION 审中-公开
标题翻译：含有二磷酸酯的药物组合物，用于改善口服吸收
公开(公告)号：WO2006080780A1
公开(公告)日：2006-08-03
申请号：PCT/KR2006/000013
申请日：2006-01-03
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
发明人： SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
IPC分类号： A61K31/663 , A61P19/10
CPC分类号： A61K9/2054 , A61K9/0095 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/205 , A61K9/2059 , A61K31/663
摘要： Provided is a pharmaceutical composition having improved oral absorption of a bisphosphonate drug, comprising at least one active substance selected from bisphosphonate drugs having non-permeability to a lipid biomembrane due to ionization and high water-solubility in vivo and having bioavailability of less than 10%, and at least one selected from biocompatible water-soluble chitosan, as essential ingredients.
摘要翻译：本发明提供了具有改善的双膦酸盐药物口服吸收的药物组合物，其包含至少一种活性物质，所述活性物质由于离子化而对脂质生物膜具有非渗透性，并且在体内具有高水溶性，并且具有小于10％的生物利用度，，和选自生物相容性水溶性壳聚糖中的至少一种作为必需成分。

4. 发明申请

WO2005123138A9 PHARMACEUTICAL PELLET COMPOSITIONS FOR CONTROLLED RELEASE 审中-公开
标题翻译：用于控制释放的药物颗粒组合物
公开(公告)号：WO2005123138A9
公开(公告)日：2006-04-06
申请号：PCT/KR2005000666
申请日：2005-03-10
申请人： CHONG KUN DANG PHARM CORP , LEE SANG-JOON , SHIN HEE-JONG , KI MIN-HYO , YOON BOK-YOUNG
发明人： LEE SANG-JOON , SHIN HEE-JONG , KI MIN-HYO , YOON BOK-YOUNG
IPC分类号： A61K9/22 , A61K9/16 , A61K47/30
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/1652
摘要： The present invention provides a pharmaceutical composition in the form of pellet wherein controlled release of pharmacologically active substances can be effected. The present invention is characterized by a pharmaceutical composition for controlled release pellets, consisting es¬ sentially of: a) one or more pharmacologically active substances; b) one or more lipids having a low-melting point of less than 70°C and existing as a solid at room temperature; c) one or more hydrophilic substances; and d) one or more water-insoluble binding agents, prepared without melting the lipids.
摘要翻译：本发明提供了丸剂形式的药物组合物，其中可以实现药理活性物质的控制释放。本发明的特征在于用于控释丸剂的药物组合物，其包括：a）一种或多种药理活性物质; b）一种或多种低熔点小于70℃并在室温下作为固体存在的脂质; c）一种或多种亲水性物质; 和d）一种或多种不溶于脂质的水不溶性结合剂。

5. 发明申请

WO2004052405A1 ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS 审中-公开
标题翻译：不良吸收性水解药物的口服制剂
公开(公告)号：WO2004052405A1
公开(公告)日：2004-06-24
申请号：PCT/KR2003/002700
申请日：2003-12-10
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , MC TECHNOLOGIES, INC. , HONG, CHUNG-IL , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa
发明人： HONG, CHUNG-IL , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa
IPC分类号： A61K47/48
CPC分类号： B82Y5/00 , A61K47/6929
摘要： Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one organic alkalizing agent having an amino acid or polyol structure which shows alkalinity in aqueous solution and is ionically bonded to the polar active substance; and (c) at least one surfactant having a C 6-18 fatty acid structure which has an HLB of 4 to 18. Alternatively, the composition consists essentially of (d) at least one organic alkalizing agent having the characteristics of both the organic alkalizing agent and the surfactant instead of the organic alkalizing agent and the surfactant. The composition enables polar active drugs to penetrate the gastro- intestinal membrane and oral dosage forms to be substituted for injections.
摘要翻译：本文公开了用于口服吸收极性药物的药物组合物。所述组合物基本上由（a）至少一种具有小于30％的生物利用度的极性活性物质组成，其通过脂质膜难以吸收，因为它具有高亲水性和带电离子; （b）至少一种具有在水溶液中显示碱度并与极性活性物质离子键合的氨基酸或多元醇结构的有机碱化剂; 和（c）至少一种具有HLB为4至18的C 6-18脂肪酸结构的表面活性剂。或者，组合物基本上由（d）至少一种具有两种有机碱化剂的有机碱化剂和表面活性剂代替有机碱化剂和表面活性剂。该组合物可使极性活性药物穿透胃肠膜和口服剂型以代替注射。

6. 发明申请

WO2013032207A1 SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：持续释放脂肪预处理药物活性物质和包含其的药物组合物
公开(公告)号：WO2013032207A1
公开(公告)日：2013-03-07
申请号：PCT/KR2012/006855
申请日：2012-08-28
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , KO, Jin Young , KIM, Ji Yeon , PARK, So Hyun , AN, Sung Won , KI, Min Hyo
发明人： KO, Jin Young , KIM, Ji Yeon , PARK, So Hyun , AN, Sung Won , KI, Min Hyo
IPC分类号： A61K9/22 , A61K9/48 , A61K9/20 , A61K47/30
CPC分类号： A61K47/22 , A61K9/0019 , A61K9/0024 , A61K9/1075 , A61K31/18 , A61K31/58 , A61K31/713 , A61K38/26 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/26 , A61K48/0016
摘要： Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more -OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.
摘要翻译：公开了一种缓释脂质预浓缩物，其包含：a）具有至少两个或更多个-OH（羟基）基团的极性头的脱水山梨糖醇不饱和脂肪酸酯; b）磷脂; 和c）不含可离子化基团的具有15至40个碳原子的疏水部分的具有三酰基或碳环结构的液晶硬化剂。脂质预浓缩物在没有水性流体的情况下以液相形式存在，并在含水流体存在下形成液晶。此外，还提供了还包含药理活性成分加上预浓缩物的药物组合物。

7. 发明申请

WO2010074460A3 NOVEL PHARMACEUTICAL COMPOSITION FOR AMELIORATING SIDE EFFECTS OF A LIPASE INHIBITOR 审中-公开
标题翻译：用于抑制脂肪酶抑制剂的副作用的新型药物组合物
公开(公告)号：WO2010074460A3
公开(公告)日：2010-09-23
申请号：PCT/KR2009007614
申请日：2009-12-18
申请人： CHONG KUN DANG PHARM CORP , KIM SUN-KYUNG , LEE SU-KYOUNG , KI MIN-HYO
发明人： KIM SUN-KYUNG , LEE SU-KYOUNG , KI MIN-HYO
IPC分类号： A61K47/30 , A61K31/337
CPC分类号： A61K31/337 , A61K47/34
摘要： The present invention relates to a novel pharmaceutical composition for ameliorating the side effects of a lipase inhibitor. More particularly, the present invention relates to a pharmaceutical composition for ameliorating the side effects of a lipase inhibitor, comprising a pharmaceutically acceptable polyalkylene oxide-based amphiphilic polymer and water-soluble thickening agents. The composition of the present invention significantly ameliorates side effects such as oily spotting, steatorrhea, or the like caused by taking a lipase inhibitor.
摘要翻译：本发明涉及一种用于改善脂肪酶抑制剂的副作用的新型药物组合物。更具体地，本发明涉及用于改善脂肪酶抑制剂的副作用的药物组合物，其包含药学上可接受的聚环氧烷基两亲性聚合物和水溶性增稠剂。本发明的组合物显着地改善了由摄取脂肪酶抑制剂引起的副作用，如油性斑点，肉眼等。

8. 发明申请

WO2005123138A1 PHARMACEUTICAL PELLET COMPOSITIONS FOR CONTROLLED RELEASE 审中-公开
标题翻译：用于控制释放的药物颗粒组合物
公开(公告)号：WO2005123138A1
公开(公告)日：2005-12-29
申请号：PCT/KR2005/000666
申请日：2005-03-10
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , LEE, Sang-Joon , SHIN, Hee-Jong , KI, Min-Hyo , YOON, Bok-Young
发明人： LEE, Sang-Joon , SHIN, Hee-Jong , KI, Min-Hyo , YOON, Bok-Young
IPC分类号： A61K47/30
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/1652
摘要： The present invention provides a pharmaceutical composition in the form of pellet wherein controlled release of pharmacologically active substances can be effected. The present invention is characterized by a pharmaceutical composition for controlled release pellets, consisting es¬ sentially of: a) one or more pharmacologically active substances; b) one or more lipids having a low-melting point of less than 70°C and existing as a solid at room temperature; c) one or more hydrophilic substances; and d) one or more water-insoluble binding agents, prepared without melting the lipids.
摘要翻译：本发明提供了丸剂形式的药物组合物，其中可以实现药理活性物质的控制释放。本发明的特征在于用于控释丸剂的药物组合物，其包括：a）一种或多种药理活性物质; b）一种或多种低熔点小于70℃并在室温下作为固体存在的脂质; c）一种或多种亲水性物质; 和d）一种或多种不溶于脂质的水不溶性结合剂。

9. 发明申请

WO2005004848A1 THE SOLID DISPERSION OF TACROLIMUS 审中-公开
标题翻译：固体分散剂
公开(公告)号：WO2005004848A1
公开(公告)日：2005-01-20
申请号：PCT/KR2004/001684
申请日：2004-07-09
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee-Jong , LIM, Jong-Lae , KI, Min-Hyo , YUN, Ji-Hun
发明人： SHIN, Hee-Jong , LIM, Jong-Lae , KI, Min-Hyo , YUN, Ji-Hun
IPC分类号： A61K9/14
CPC分类号： A61K9/145 , A61K9/1617 , A61K9/1676 , A61K31/4523 , A61K38/13
摘要： The present invention relates to the carrier of the solid dispersion of tacrolimus, which is prepared by using the solid surfactant having a property of HLB value higher than or equal to about 7. The surfactants carry out a function of a carrier and a function of a dissolution enhancer, simultaneously. As a result, the dissolution rate of tacrolimus is improved, and the oral absorbability and the bioavailability may be increased due to rapid drug release.
摘要翻译：本发明涉及通过使用具有HLB值高于或等于约7的性质的固体表面活性剂制备的他克莫司的固体分散体的载体。表面活性剂具有载体的功能和作用溶解增强剂，同时。结果，他克莫司的溶出速度提高，口服吸收性和生物利用度可能由于快速的药物释放而增加。

10. 发明申请

WO2006033505A1 PAROXETINE CHOLATE OR CHOLIC ACID DERIVATIVE SALTS, AND COMPOSITION COMPRISING PAROXETINE AND CHOLIC ACID OF CHOLIC ACID DERIVATIVES 审中-公开
标题翻译：异黄酮或胆酸衍生物，以及包含胆酸和胆酸的化合物的组合物
公开(公告)号：WO2006033505A1
公开(公告)日：2006-03-30
申请号：PCT/KR2004/003477
申请日：2004-12-28
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , LEE, Sang Joon , SHIN, Hee Jong , KI, Min Hyo , LEE, Su Kyoung , KIM, Bok Young , LEE, Hong Woo
发明人： LEE, Sang Joon , SHIN, Hee Jong , KI, Min Hyo , LEE, Su Kyoung , KIM, Bok Young , LEE, Hong Woo
IPC分类号： C07D405/12
CPC分类号： C07D405/12 , C07J43/00
摘要： Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.
摘要翻译：本文公开了帕罗西汀胆酸盐或胆酸衍生物盐和包含帕罗西汀和胆酸或其衍生物的组合物。还公开了包含帕罗西汀盐或组合物的药物组合物。作为帕罗西汀的口腔崩解片剂，可以将药物组合物配制成无水的口服制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式